The role of sentinel lymph node biopsy for melanoma.
Identifieur interne : 004498 ( PubMed/Curation ); précédent : 004497; suivant : 004499The role of sentinel lymph node biopsy for melanoma.
Auteurs : Jeannie Shen [États-Unis] ; Anne M. Wallace ; Michael BouvetSource :
- Seminars in oncology [ 0093-7754 ] ; 2002.
Descripteurs français
- KwdFr :
- Agents colorants, Biopsie de noeud lymphatique sentinelle (), Complications postopératoires (), Faux négatifs, Humains, Lymphadénectomie (effets indésirables), Mélanome (anatomopathologie), Mélanome (imagerie diagnostique), Mélanome (secondaire), Métastase lymphatique (anatomopathologie), Métastase lymphatique (imagerie diagnostique), Noeuds lymphatiques (anatomopathologie), Noeuds lymphatiques (imagerie diagnostique), Pronostic, Radiopharmaceutiques, Scintigraphie, Stade de la tumeur, Sélection de patients, Taux de survie, Tumeurs cutanées (anatomopathologie), Valeur prédictive des tests.
- MESH :
- anatomopathologie : Mélanome, Métastase lymphatique, Noeuds lymphatiques, Tumeurs cutanées.
- effets indésirables : Lymphadénectomie.
- imagerie diagnostique : Mélanome, Métastase lymphatique, Noeuds lymphatiques.
- secondaire : Mélanome.
- Agents colorants, Biopsie de noeud lymphatique sentinelle, Complications postopératoires, Faux négatifs, Humains, Pronostic, Radiopharmaceutiques, Scintigraphie, Stade de la tumeur, Sélection de patients, Taux de survie, Valeur prédictive des tests.
English descriptors
- KwdEn :
- Coloring Agents, False Negative Reactions, Humans, Lymph Node Excision (adverse effects), Lymph Nodes (diagnostic imaging), Lymph Nodes (pathology), Lymphatic Metastasis (diagnostic imaging), Lymphatic Metastasis (pathology), Melanoma (diagnostic imaging), Melanoma (pathology), Melanoma (secondary), Neoplasm Staging, Patient Selection, Postoperative Complications (prevention & control), Predictive Value of Tests, Prognosis, Radionuclide Imaging, Radiopharmaceuticals, Sentinel Lymph Node Biopsy (classification), Sentinel Lymph Node Biopsy (methods), Skin Neoplasms (pathology), Survival Rate.
- MESH :
- chemical : Coloring Agents, Radiopharmaceuticals.
- adverse effects : Lymph Node Excision.
- classification : Sentinel Lymph Node Biopsy.
- diagnostic imaging : Lymph Nodes, Lymphatic Metastasis, Melanoma.
- methods : Sentinel Lymph Node Biopsy.
- pathology : Lymph Nodes, Lymphatic Metastasis, Melanoma, Skin Neoplasms.
- prevention & control : Postoperative Complications.
- secondary : Melanoma.
- False Negative Reactions, Humans, Neoplasm Staging, Patient Selection, Predictive Value of Tests, Prognosis, Radionuclide Imaging, Survival Rate.
Abstract
Regional lymph nodes are a common site of melanoma metastases, and the presence or absence of melanoma in regional lymph nodes is the single most important prognostic factor for predicting survival. Furthermore, identification of metastatic melanoma in lymph nodes and excision of these nodes may enhance survival in a subgroup of patients whose melanoma has metastasized only to their regional lymph nodes and not to distant sites. Sentinel lymph node (SLN) biopsy was developed as a low morbidity technique to stage the lymphatic basin without the potential morbidity of lymphedema and nerve injury. The presence or absence of metastatic melanoma in the SLN accurately predicts the presence or absence of metastatic melanoma in that lymph node basin. When performed by experienced centers, the false-negative rate of SLN biopsy is very low. As such, the nodal basin that contains a negative SLN will usually be free of microscopic disease. Since occult micrometastatic disease affects only 12% to 15% of patients with melanoma, selective SLN dissection allows up to 85% of patients with melanoma to be spared a formal lymph node dissection, thus avoiding the complications usually associated with that procedure. While standard pathologic evaluation of lymph nodes may miss metastatic melanoma cells, more sensitive techniques are developing which may identify micrometastases more accurately. The clinical significance of these micrometastases remains unknown and is the subject of active investigations.
PubMed: 12170437
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :004498
Links to Exploration step
pubmed:12170437Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The role of sentinel lymph node biopsy for melanoma.</title>
<author><name sortKey="Shen, Jeannie" sort="Shen, Jeannie" uniqKey="Shen J" first="Jeannie" last="Shen">Jeannie Shen</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Surgery, University of California, San Diego, CA 92161, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Surgery, University of California, San Diego, CA 92161</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Wallace, Anne M" sort="Wallace, Anne M" uniqKey="Wallace A" first="Anne M" last="Wallace">Anne M. Wallace</name>
</author>
<author><name sortKey="Bouvet, Michael" sort="Bouvet, Michael" uniqKey="Bouvet M" first="Michael" last="Bouvet">Michael Bouvet</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2002">2002</date>
<idno type="RBID">pubmed:12170437</idno>
<idno type="pmid">12170437</idno>
<idno type="wicri:Area/PubMed/Corpus">004498</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">004498</idno>
<idno type="wicri:Area/PubMed/Curation">004498</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">004498</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">The role of sentinel lymph node biopsy for melanoma.</title>
<author><name sortKey="Shen, Jeannie" sort="Shen, Jeannie" uniqKey="Shen J" first="Jeannie" last="Shen">Jeannie Shen</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Surgery, University of California, San Diego, CA 92161, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Surgery, University of California, San Diego, CA 92161</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Wallace, Anne M" sort="Wallace, Anne M" uniqKey="Wallace A" first="Anne M" last="Wallace">Anne M. Wallace</name>
</author>
<author><name sortKey="Bouvet, Michael" sort="Bouvet, Michael" uniqKey="Bouvet M" first="Michael" last="Bouvet">Michael Bouvet</name>
</author>
</analytic>
<series><title level="j">Seminars in oncology</title>
<idno type="ISSN">0093-7754</idno>
<imprint><date when="2002" type="published">2002</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Coloring Agents</term>
<term>False Negative Reactions</term>
<term>Humans</term>
<term>Lymph Node Excision (adverse effects)</term>
<term>Lymph Nodes (diagnostic imaging)</term>
<term>Lymph Nodes (pathology)</term>
<term>Lymphatic Metastasis (diagnostic imaging)</term>
<term>Lymphatic Metastasis (pathology)</term>
<term>Melanoma (diagnostic imaging)</term>
<term>Melanoma (pathology)</term>
<term>Melanoma (secondary)</term>
<term>Neoplasm Staging</term>
<term>Patient Selection</term>
<term>Postoperative Complications (prevention & control)</term>
<term>Predictive Value of Tests</term>
<term>Prognosis</term>
<term>Radionuclide Imaging</term>
<term>Radiopharmaceuticals</term>
<term>Sentinel Lymph Node Biopsy (classification)</term>
<term>Sentinel Lymph Node Biopsy (methods)</term>
<term>Skin Neoplasms (pathology)</term>
<term>Survival Rate</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Agents colorants</term>
<term>Biopsie de noeud lymphatique sentinelle ()</term>
<term>Complications postopératoires ()</term>
<term>Faux négatifs</term>
<term>Humains</term>
<term>Lymphadénectomie (effets indésirables)</term>
<term>Mélanome (anatomopathologie)</term>
<term>Mélanome (imagerie diagnostique)</term>
<term>Mélanome (secondaire)</term>
<term>Métastase lymphatique (anatomopathologie)</term>
<term>Métastase lymphatique (imagerie diagnostique)</term>
<term>Noeuds lymphatiques (anatomopathologie)</term>
<term>Noeuds lymphatiques (imagerie diagnostique)</term>
<term>Pronostic</term>
<term>Radiopharmaceutiques</term>
<term>Scintigraphie</term>
<term>Stade de la tumeur</term>
<term>Sélection de patients</term>
<term>Taux de survie</term>
<term>Tumeurs cutanées (anatomopathologie)</term>
<term>Valeur prédictive des tests</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Coloring Agents</term>
<term>Radiopharmaceuticals</term>
</keywords>
<keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Lymph Node Excision</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Mélanome</term>
<term>Métastase lymphatique</term>
<term>Noeuds lymphatiques</term>
<term>Tumeurs cutanées</term>
</keywords>
<keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Sentinel Lymph Node Biopsy</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Lymph Nodes</term>
<term>Lymphatic Metastasis</term>
<term>Melanoma</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Lymphadénectomie</term>
</keywords>
<keywords scheme="MESH" qualifier="imagerie diagnostique" xml:lang="fr"><term>Mélanome</term>
<term>Métastase lymphatique</term>
<term>Noeuds lymphatiques</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Sentinel Lymph Node Biopsy</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Lymph Nodes</term>
<term>Lymphatic Metastasis</term>
<term>Melanoma</term>
<term>Skin Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Postoperative Complications</term>
</keywords>
<keywords scheme="MESH" qualifier="secondaire" xml:lang="fr"><term>Mélanome</term>
</keywords>
<keywords scheme="MESH" qualifier="secondary" xml:lang="en"><term>Melanoma</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>False Negative Reactions</term>
<term>Humans</term>
<term>Neoplasm Staging</term>
<term>Patient Selection</term>
<term>Predictive Value of Tests</term>
<term>Prognosis</term>
<term>Radionuclide Imaging</term>
<term>Survival Rate</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Agents colorants</term>
<term>Biopsie de noeud lymphatique sentinelle</term>
<term>Complications postopératoires</term>
<term>Faux négatifs</term>
<term>Humains</term>
<term>Pronostic</term>
<term>Radiopharmaceutiques</term>
<term>Scintigraphie</term>
<term>Stade de la tumeur</term>
<term>Sélection de patients</term>
<term>Taux de survie</term>
<term>Valeur prédictive des tests</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Regional lymph nodes are a common site of melanoma metastases, and the presence or absence of melanoma in regional lymph nodes is the single most important prognostic factor for predicting survival. Furthermore, identification of metastatic melanoma in lymph nodes and excision of these nodes may enhance survival in a subgroup of patients whose melanoma has metastasized only to their regional lymph nodes and not to distant sites. Sentinel lymph node (SLN) biopsy was developed as a low morbidity technique to stage the lymphatic basin without the potential morbidity of lymphedema and nerve injury. The presence or absence of metastatic melanoma in the SLN accurately predicts the presence or absence of metastatic melanoma in that lymph node basin. When performed by experienced centers, the false-negative rate of SLN biopsy is very low. As such, the nodal basin that contains a negative SLN will usually be free of microscopic disease. Since occult micrometastatic disease affects only 12% to 15% of patients with melanoma, selective SLN dissection allows up to 85% of patients with melanoma to be spared a formal lymph node dissection, thus avoiding the complications usually associated with that procedure. While standard pathologic evaluation of lymph nodes may miss metastatic melanoma cells, more sensitive techniques are developing which may identify micrometastases more accurately. The clinical significance of these micrometastases remains unknown and is the subject of active investigations.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12170437</PMID>
<DateCreated><Year>2002</Year>
<Month>08</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted><Year>2002</Year>
<Month>09</Month>
<Day>05</Day>
</DateCompleted>
<DateRevised><Year>2016</Year>
<Month>11</Month>
<Day>24</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0093-7754</ISSN>
<JournalIssue CitedMedium="Print"><Volume>29</Volume>
<Issue>4</Issue>
<PubDate><Year>2002</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Seminars in oncology</Title>
<ISOAbbreviation>Semin. Oncol.</ISOAbbreviation>
</Journal>
<ArticleTitle>The role of sentinel lymph node biopsy for melanoma.</ArticleTitle>
<Pagination><MedlinePgn>341-52</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Regional lymph nodes are a common site of melanoma metastases, and the presence or absence of melanoma in regional lymph nodes is the single most important prognostic factor for predicting survival. Furthermore, identification of metastatic melanoma in lymph nodes and excision of these nodes may enhance survival in a subgroup of patients whose melanoma has metastasized only to their regional lymph nodes and not to distant sites. Sentinel lymph node (SLN) biopsy was developed as a low morbidity technique to stage the lymphatic basin without the potential morbidity of lymphedema and nerve injury. The presence or absence of metastatic melanoma in the SLN accurately predicts the presence or absence of metastatic melanoma in that lymph node basin. When performed by experienced centers, the false-negative rate of SLN biopsy is very low. As such, the nodal basin that contains a negative SLN will usually be free of microscopic disease. Since occult micrometastatic disease affects only 12% to 15% of patients with melanoma, selective SLN dissection allows up to 85% of patients with melanoma to be spared a formal lymph node dissection, thus avoiding the complications usually associated with that procedure. While standard pathologic evaluation of lymph nodes may miss metastatic melanoma cells, more sensitive techniques are developing which may identify micrometastases more accurately. The clinical significance of these micrometastases remains unknown and is the subject of active investigations.</AbstractText>
<CopyrightInformation>Copyright 2002, Elsevier Science (USA). All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shen</LastName>
<ForeName>Jeannie</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Department of Surgery, University of California, San Diego, CA 92161, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wallace</LastName>
<ForeName>Anne M</ForeName>
<Initials>AM</Initials>
</Author>
<Author ValidYN="Y"><LastName>Bouvet</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Semin Oncol</MedlineTA>
<NlmUniqueID>0420432</NlmUniqueID>
<ISSNLinking>0093-7754</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004396">Coloring Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D004396" MajorTopicYN="N">Coloring Agents</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005188" MajorTopicYN="N">False Negative Reactions</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008197" MajorTopicYN="N">Lymph Node Excision</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008198" MajorTopicYN="N">Lymph Nodes</DescriptorName>
<QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008207" MajorTopicYN="N">Lymphatic Metastasis</DescriptorName>
<QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008545" MajorTopicYN="N">Melanoma</DescriptorName>
<QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
<QualifierName UI="Q000556" MajorTopicYN="Y">secondary</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018579" MajorTopicYN="N">Patient Selection</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011877" MajorTopicYN="N">Radionuclide Imaging</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D021701" MajorTopicYN="Y">Sentinel Lymph Node Biopsy</DescriptorName>
<QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012878" MajorTopicYN="N">Skin Neoplasms</DescriptorName>
<QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>64</NumberOfReferences>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year>
<Month>8</Month>
<Day>10</Day>
<Hour>10</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2002</Year>
<Month>9</Month>
<Day>6</Day>
<Hour>10</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2002</Year>
<Month>8</Month>
<Day>10</Day>
<Hour>10</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">12170437</ArticleId>
<ArticleId IdType="pii">S0093775402502645</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004498 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 004498 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:12170437 |texte= The role of sentinel lymph node biopsy for melanoma. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:12170437" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
![]() | This area was generated with Dilib version V0.6.31. | ![]() |